A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis

被引：14
|
作者：
Hansel, K. [1 ]
Zangrilli, A. [2 ]
Bianchi, L. [1 ,2 ]
Peris, K. [3 ]
Chiricozzi, A. [3 ]
Offidani, A. [4 ]
Diotallevi, F. [4 ]
Fargnoli, M. C. [5 ]
Esposito, M. [5 ]
Amerio, P. [6 ]
Gualdi, G. [6 ]
Bianchi, L. [1 ,2 ]
Stingeni, L. [1 ]
机构：
[1] Univ Perugia, Dept Med & Surg, Dermatol Sect, Perugia, Italy
[2] Univ Roma Tor Vergata, Dept Syst Med, Policlin Tor Vergata, Dermatol Unit, Rome, Italy
[3] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Med & Chirurg, Dermatol, Rome, Italy
[4] Polytech Univ Marche Reg, Dept Clin & Mol Sci, Dermatol Clin, Ancona, Italy
[5] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Dermatol, Laquila, Italy
[6] Univ G dAnnunzio, Dermatol Clin, Dept Med & Aging Sci, Chieti, Italy
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2022年 / 36卷 / 02期
关键词：
D O I：
10.1111/jdv.17656
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E111 / E113
页数：3
相关论文
共 50 条
  • [31] Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period
    Megna, Matteo
    Cinelli, Eleonora
    Gallo, Lucia
    Camela, Elisa
    Ruggiero, Angelo
    Fabbrocini, Gabriella
    [J]. ARCHIVES OF DERMATOLOGICAL RESEARCH, 2022, 314 (06) : 619 - 623
  • [32] Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic
    Gkalpakiotis, Spyridon
    Cetkovska, Petra
    Arenberger, Petr
    Dolezal, Tomas
    Arenbergerova, Monika
    Velackova, Barbora
    Fialova, Jorga
    Kojanova, Martina
    [J]. DERMATOLOGY AND THERAPY, 2021, 11 (04) : 1345 - 1355
  • [33] Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study
    Benhadou, F.
    Ghislain, P. D.
    Guiot, F.
    Willaert, F.
    Del Marmol, V.
    Lambert, J.
    Soenen, R.
    Fierens, H.
    de la Brassinne, M.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (12) : E837 - E839
  • [34] Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study
    Ostor, Andrew
    van den Bosch, Filip
    Papp, Kim
    Asnal, Cecilia
    Blanco, Ricardo
    Aelion, Jacob
    Lu, Wenjing
    Wang, Zailong
    Soliman, Ahmed M.
    Eldred, Ann
    Padilla, Byron
    Kivitz, Alan
    [J]. RHEUMATOLOGY, 2023, 62 (06) : 2122 - 2129
  • [35] Effectiveness and Safety of Ocrelizumab - Real-life Experience of a Tertiary Center
    Carvalho, Ines V.
    Cunha, Carolina
    Nunes, Carla
    Macario, Maria do Carmo
    Batista, Sonia
    Sousa, Livia Maria
    Correia, Ines
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1006 - 1007
  • [36] Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic
    Spyridon Gkalpakiotis
    Petra Cetkovska
    Petr Arenberger
    Tomas Dolezal
    Monika Arenbergerova
    Barbora Velackova
    Jorga Fialova
    Martina Kojanova
    [J]. Dermatology and Therapy, 2021, 11 : 1345 - 1355
  • [37] Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study
    Kristensen, Lars Erik
    Keiserman, Mauro
    Papp, Kim
    McCasland, Leslie
    White, Douglas
    Lu, Wenjing
    Soliman, Ahmed M.
    Eldred, Ann
    Barcomb, Lisa
    Behrens, Frank
    [J]. RHEUMATOLOGY, 2023, 62 (06) : 2113 - 2121
  • [38] A head-to-head comparison of risankizumab and ixekizumab for genital psoriasis: a real-life, 24-week, prospective study
    Sotiriou, E.
    Bakirtzi, K.
    Papadimitriou, I.
    Tsentemeidou, A.
    Eftychidou, P.
    Eleftheriadis, V.
    Lallas, A.
    Ioannides, D.
    Vakirlis, E.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (05) : E359 - E361
  • [39] A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis
    Fargnoli, M. C.
    Esposito, M.
    Ferrucci, S.
    Girolomoni, G.
    Offidani, A.
    Patrizi, A.
    Peris, K.
    Costanzo, A.
    Malara, G.
    Pellacani, G.
    Romanelli, M.
    Amerio, P.
    Cristaudo, A.
    Flori, M. L.
    Motolese, A.
    Betto, P.
    Patruno, C.
    Pigatto, P.
    Peccianti, C.
    Stinco, G.
    Zalaudek, I.
    Bianchi, L.
    Boccaletti, V.
    Cannavo, S. P.
    Cusano, F.
    Lembo, S.
    Mozzillo, R.
    Gallo, R.
    Potenza, C.
    Rongioletti, F.
    Tiberio, R.
    Grieco, T.
    Micali, G.
    Persechino, S.
    Pettinato, M.
    Pucci, S.
    Stingeni, L.
    Caruso, C.
    Argenziano, G.
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 1146 - 1149
  • [40] Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience
    Bardazzi, Federico
    Viviani, Filippo
    Merli, Yuri
    Di Lernia, Vito
    Peccerillo, Francesca
    Conti, Andrea
    Lasagni, Claudia
    Tabanelli, Michela
    D'Adamio, Simone
    Di Nuzzo, Sergio
    Cortellazzi, Chiara
    Filippi, Federica
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (12) : 1561 - 1566
12345